Previous 10 | Next 10 |
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences PR Newswire SOUTH PLAINFIELD, N.J., Oct. 28, 2020 SOUTH PLAINFIELD, N.J. , Oct. 28, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will p...
PTC Therapeutics ([[PTCT]] +0.2%) initiates a Phase 2/3 clinical trial, MIT-E, evaluating vatiquinone (PTC743) in patients with mitochondrial epilepsy, a rare highly morbid disorder characterized by treatment-resistant seizures in children with inherited mitochondrial disease.The primary endp...
PTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial Epilepsy - Global Phase 2/3 trial now enrolling patients with highly morbid unmet medical condition - PR Newswire SOUTH PLAINFIELD, N.J., Oct. 26, 202...
PTC Therapeutics and AADC Family Network Announce First-Ever AADC Deficiency Awareness Day in Massachusetts - Massachusetts signs proclamation declaring Oct.23 as AADC Deficiency Awareness Day - - PTC hosts Facebook Live event featuring leaders from AADC Family Network, Mass...
Brazil's National Health Surveillance Agency has approved PTC Therapeutics's ([[PTCT]] +1.0%) Evrysdi (risdiplam) for the treatment of spinal muscular atrophy ((SMA)).Additionally, PTC filed marketing application seeking approval for Evrysdi in Japan. The filing in Japan by Chugai P...
Evrysdi™ (risdiplam) Continues to Make Global Progress for the Treatment of Spinal Muscular Atrophy - Broad approval in Brazil based on data from multiple pivotal trials - - NDA filed with Japan's MHLW under Priority Review; Milestone triggers $7.5M payment from Roche...
PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2020 Financial Results PR Newswire SOUTH PLAINFIELD, N.J., Oct. 15, 2020 SOUTH PLAINFIELD, N.J. , Oct. 15, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Co...
20 Gene Therapy Clinical Trials Using the ClearPoint platform. Utilizes Razor / Blades Business Model. Disposables and Biologics ("Blades") revenues up 183% in Q2 2020. Significant Operating Leverage: Past 5 Years SG&A up ~20% while Gross Profit was up Over 300%. Large...
PTC Therapeutics reports positive 2-year data for Evrysdi. Inovio stumbles as the FDA places a partial hold on the COVID-19 vaccine trial. Sarepta reports encouraging data for investigational Duchenne Muscular Dystrophy gene therapy. For further details see: PTC Therapeu...
PTC Therapeutics (PTCT) and exclusive licensee Genentech, a unit of Roche (RHHBY), announce two-year data from Part 1 of the pivotal Phase 2/3 FIREFISH study evaluating Evrysdi (risdiplam) in infants aged 2-7 months with symptomatic Type 1 spinal muscular atrophy ((SMA)). Infants treated rece...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....